UK-based NextPharma Technologies has been selected by Mitsubishi Pharma Europe (MPE) to provide tailored, primary and secondary packaging solutions for its BindRen, within the European territory.
MPE, the European subsidiary of Mitsubishi Tanabe Pharma, selected NextPharma as its fully-serviced outsourcing partner for the European launch of BindRen, which has already been launched in Germany and Austria.
MPE vice president Toshiaki Mikuni said the company was on look out for a partner with a significant European presence and selected the packaging solutions available at NextPharma's solids facility in Germany.
"This is an important, high-profile launch for Mitsubishi and selecting a partner who could quickly grasp our needs and add value to our goals was essential," Mikuni said.
The orally available non-absorbed anion exchange resin BindRen is used for the treatment of hyperphosphataemia in adult patients with Chronic Kidney Disease (CKD) Stage 5 receiving haemodialysis or peritoneal dialysis.
NextPharma operates globally with six product development centers, six manufacturing plants and six temperature controlled storage and distribution sites across Europe. It provides a range of services from early phase product development, through clinical trial packaging to high volume commercial manufacturing.
